Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 2 of 2 range targets
Below the range 0 below the last range given

The numbers OGN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
– Not reported yet
The company's words
For full year 2026, the company expects to achieve revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion; both measures in-line with 2025 performance. release Feb 12, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $6.12B to $6.33B release Feb 13, 2025
Raised $6.28B to $6.38B release Aug 5, 2025
Lowered $6.20B to $6.25B release Nov 10, 2025
$6.22B
10-K filed 2026-02-24
Within the range
The company's words
Full year revenue range of $6.125 billion - $6.325 billion, inclusive of · an approximate $200 million year-over-year negative impact from foreign exchange release Feb 13, 2025
Previous Guidance as of Current May 1, 2025 Guidance … Revenue $6.275B - $6.375B release Aug 5, 2025
Previous Guidance as of August 5, 2025 Current Guidance … Revenue $6.200B - $6.250B release Nov 10, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $6.20B to $6.50B release Feb 15, 2024
Narrowed $6.25B to $6.45B release Aug 6, 2024
Raised $6.38B to $6.42B release Oct 31, 2024
$6.40B
10-K filed 2025-02-28
Within the range
The company's words
Full · year 2024 financial guidance ranges provided; full year revenue range of $6.2 billion to $6.5 billion and Adjusted EBITDA margin in the range of 31.0% to 33.0% release Feb 15, 2024
Guidance range for full year 2024 revenue narrowed to $6.250 billion to $6.450 · billion, mid-point of the range, affirmed; release Aug 6, 2024
Guidance range for full year 2024 revenue narrowed to $6.375 billion to $6.425 billion, mid-point of the range raised by $50 million; · Guidance range for Adjusted EBITDA margin (non-GAAP) revised to 30.0% to 31.0%, inclusive of the $51 million of IPR&D expense incurred in the third quarter release Oct 31, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (10 releases since 2024-02-15), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.